We describe a fully automated particle-enhanced turbidimetric assay for cystatin C in undiluted serum and EDTAplasma. The throughput is 90 samples per hour and urgent samples can be analyzed in 7 mm. The assay range (0.4-14.1 mgIL) covers the concentration range in health and disease. The within-and between-run imprecision is 0.9% and 2.2%, respectively. Analytical recovery of additions of recombinant cystatin C averaged 98%. Rheumatoid factors ( 323 000 lU/L), bilirubin ( 150 mol/L), hemoglobin ( 1.2 g/L), and triglycerides ( 8.5 mmol/L) do not interfere in the assay. In view of the superior (by ROC analysis) diagnostic accuracy of serum concentrations of cystatin C for reduced glomerular filtration rate (GFR) in comparison with creatinine, cystatin C seems an attractive alternative to creatinine for estimation of GFR.
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Cystatin
C is a nonglycosylated 13-kDa basic protein of the cystatin super-family of cysteine proteinase inhibitors (1) (2) (3) (4) . Produced by all investigated nucleated cells, its production rate is unaltered in inflammatory conditions (4) (5) (6) (7) (8) . Determination of the structure of the cystatin C gene and its promoter has shown that the gene is of the house-keeping type, which is compatible with a stable production rate of cystatin C by most cell types (7). The low molecular mass of cystatin C, in combination with its stable production rate, strongly suggests that the major determinant of cystatin C concentrations in blood plasma is the glomerular filtration rate (GFR).6 Three investigations, employing enzyme-amplified single radial immunodiffusion to quantiVy cystatin C, supported this hypothesis and demonstrated that the serum concentration of cystatin C is at least as good an indicator for GFR as that of creatinine (5, 6, 9). A recent investigation with enzyme-linked immunoassay for determining cystatin C also supports this hypothesis (10). However, the reported methods for quantification of cys- Here, we describe the development of a rapid, automated method for determining serum and plasma concentrations of cystatin C, based upon particle-enhanced turbidimetry (PET). We tested the method with samples from a group of patients with normal to markedly reduced GFR to investigate whether the cystatin C measurement was a better marker than serum creatinine for GFR.
Materials and Methods
Materials
A Cobas Fara instrument (F. Hoffmann-La Roche, Basel, Switzerland), an automated single-unit centrifugal analyzer, was used for the development of the present PET assay of cystatin C. The light source is a high-intensity xenon flash used with a holographically inscribed grating monochromator.
The change in absorbance at 340 nm was measured.
Cystatin C immunoparticles. Carboxylate-modifled latex particles, 38 nm in diameter, were obtained from Duke Scientific Corp., Palo Alto, CA. Rabbit antibodies against human cystatin C were from Dako, Glostrup, Denmark (code no. A 451). We covalently attached the antibodies to the uniform microparticles by a carbodiimide reaction (11, 12). The immunoparticles were used at a final concentration of -4 g/L. The number of IgG molecules on each particle was -32.
Cystatin C-free normal human serum. To produce a suitable matrix for developing a quantitative assay for cystatin C, we diluted 50 mL of a serum pool from 10 healthy volunteers with an equal volume of 0.05 mol/L Tris buffer, pH 7.4, containing 0.5 molIL sodium chloride. To this solution was then added 20 mL of CNBrSepharose with 10 mg of the IgG fraction of polyclonal rabbit antiserum against human cystatin C covalently coupled per milliliter.
The mixture was gently rocked at room temperature for 2 h and the CNBr-Sepharose removed by ifitration on a glass filter funnel. The resulting solution was concentrated to 50 mL by pressure ultrafiltration with a membrane having a nominal retention limit of 10 kDa. Enzyme-amplified single radial immunodiffusion (9) was used to corroborate the complete removal of cystatin C from the serum pool.
Calibrator.
Lyophilized recombinant human cystatin C produced and isolated as described earlier (13,14) was used to prepare the calibrator.
Agarose and sodium do- To obtain samples with various hemoglobin concentrations, we prepared as earlier described ( 
Patients' Samples
Serum
and EDTA-treated plasma samples from healthy subjects and from patients with decreased GFR or increased concentrations of rheumatoid factor or TG were investigated.
The rheumatoid factor values were estimated by an ELISA method (19) . To analyze the relationships between GFR, cystatin C, and creatinine concentrations, we used serum samples from 27 male and 24 female patients (ages 8-Si years) with various renal conditions. Their GFR, determined as described below, ranged from 7 to 141 mL/min per 1.73 m2 body surface (reference range 80-120 mL/min per 1.73 m2). The procedures involving patients and healthy subjects were in accordance with the Helsinki Declaration of 1975.
Final Assay Procedure
The following protocol was found to be optimal for routine assay of cystatin C in serum and plasma and was used in subsequent experiments. The assay is performed at 37#{176}C with a seven-point cystatin C calibration curve covering the range 0.4-14.1 mg/L (produced with solutions of isolated recombinant cystatin C). The assay steps are: 20 1zL of sample (or calibrator)
is pipetted into a cuvette followed by 10 jtL of distilled water for washing and 230 iL of reaction buffer. The rotor is spun for 120 s, after which a sample blank recording is made at 340 nm. Thereafter, 21 L of a cystatin C immunopartide suspension is added, followed by 20 L of distified water for washing.
The increase in absorbance at 340 nm produced by the agglutination reaction is then measured after 240 s to give an endpoint value. After endpoint values are corrected for sample blanks and reagent blank, the results are calculated in the Cobas Fara instrument by logit-log function analysis. The throughput of the procedure is 90 samples per hour, and urgent samples can be analyzed in 7 mm.
Other Procedures
Determination of GFR. GFR was determined by measuring the plasma clearance of iohexol (20), a radiocontrast agent used as a reliable marker for GFR (21) . Clearance was calculated from iohexol concentrations in four plasma samples drawn 3-4 h after injection of the marker. The method has a total variation (CV) of 11%, most of which is accounted for by biological variation (20) . In patients with markedly reduced renal function (serum creatinine >200 prnol/L), the sampling period was extended to as much as 48 h to ensure correct determination of the slope of the elimination curve. Imprecision.
Serum
To determine within-run, between-run, and total imprecision, we analyzed five serum pools with cystatin C values between 084 and 4.24 mgIL. The imprecision was calculated by using a one-way analysis of variance (ANOVA). Data from five replicate analyses assayed in six different runs (days) were compiled (Table 1). The within-run imprecision averaged 0.9% and never exceeded 2%, the between-run imprecision averaged 2.2%, and the total imprecision averaged 2.4% and was always below 3.2%.
Analytical recovery. Supplemented samples were prepared by adding different amounts of a recombinant cystatin C solution (64.4 mgfL) to three normal donor samples of known concentration.
The percentage recovery was calculated as the percentage ratio between the measured and added concentrations of cystatin C. The average analytical recovery of cystatin C was 98% (Table 2) .
Interference tests. To assess whether hyperlipemia interferes in the assay, we analyzed patients' samples of known increased TG concentrations after supplementing the samples with the cystatin C calibrator (17.6 mg/L) and by dilution experiments.
Testing for linear- bilirubin the cystatin C concentrations in samples were slightly higher than expected. The increase was <10%, however.
Interference from hemoglobin was investigated in six normal donors' serum samples or EDTA-plasma sampies with added hemoglobin. Hemoglobin concentrations 1.2 g/L did not interfere in the assay. The average value after three cycles was 102% (SD 6%) of that before freezing.
Serum Cystatin C and Creatinine as Markers for GFR
When data from all 51 patients were included in the calculations, both the serum creatinine and the cystatin C concentrations were significantly related to GFR (Table 3, Fig. 2) . The correlation between the reciprocal cystatin C concentration and GFR (r = 0.87) was significantly stronger than that between the reciprocal creatinine concentration and GFR (r = 0.71). Fig. 2 makes evident that these significant relationships were largely accounted for by data from patients with reduced renal function.
However, although there was no significant relationship between the reciprocal creatinine concentration and GFR in subjects with normal GFR, the correlation between the reciprocal cystatin C concentration and GFR extended over the entire GFR range and remained significant also in subjects with normal renal function ( Table 3) .
The cystatin C concentrations of the limited number of subjects (27) with normal GFR (>80 mllmin per 1.73 m2) ranged from 0.61 to 1.21 mgfL and may be used to define a preliminary reference interval.
No sex-related difference was observed.
Diagnostic Accuracy of Serum Cystatin C and Creatinine
ROC plots describe the alterations in diagnostic sensitivity and specificity that occur when the (hypothetical) cutoff limit is gradually increased.
As demonstrated in Fig. 3 , the cutoff limit for cystatin C can be increased to correspond to a sensitivity of almost 70% while maintaining 100% specificity.
Increasing the cystatin C cutoff limit so as to attain 100% sensitivity moderately reduces the specificity (to -75%). In contrast, the specificity of the Table 3 . CorrelatIon between GFR and creatinine and cystatln C concentrations In plasma of 51 patients. serum concentration of creatinine begins to decrease at a cutoff limit corresponding to a sensitivity of <50%. A sensitivity of 100% for serum creatinine would require a cutoff limit yielding a specificity of close to zero. The areas under the curves differed significantly (P <0.001), demonstrating that the diagnostic accuracy of the serum concentration of cystatin C is superior to that of creatinine.
Discussion
Three earlier studies, using enzyme-amplified single radial immunodiffusion to determine the concentration of cystatin C, indicated that this value might be as good a marker for GFR as the concentration of creatinine (5, 6, 9). However, radial immunodiffusion procedures are generally much slower and less precise than the available procedures for determining creatinine. Therefore it is important to develop automated, rapid, and precise methods for quantifying cystatin C in serum and plasma to exploit the diagnostic potential of cystatin C in clinical practice. The present cystatin C assay by PET fulfills all these criteria. The PET technology significantly increases the sensitivity of turbidimetric assays and allows determination of protein concentrations at least 10-to 100-fold below what can be determined by conventional nonenhanced assays. The detection limit of the present PET assay of cystatin C is 0. 15 5, 6, 9, 10, 23-27) .
The sensitivity of the present method is lower than that reported for previous methods based upon enzyme-labeled or radioactive reagents, but its assay range comprises (without sample dilution) the entire span of serum concentrations of cystatin C seen in healthy subjects and in the vast majority of sick individuals (5, 6, 9, 10, 23-25). The mean cystatin C concentration determined in subjects with normal GFR by the present PET assay was 0.86 (range 0.61-1.21) mgfL, which is compatible with the concentration ranges for healthy persons given by most earlier reports on concentration of human cystatin C (5, 6, 9, 23-25) .
Comparisons of the relations between cystatin C and creatinine concentrations and GFR are greatly influenced by the selection of the population studied. Evaluations that include mainly subjects with normal renal flmction generally produce weaker correlations, whereas clinical studies that include patients with markedly reduced renal function tend to give much stronger relationships because of polarization of the data. Our study group represents a typical clinical material and is therefore likely to produce clinically relevant information.
Our results (Table 3 , Figs. 2 and 3) demonstrate that the serum concentration of cystatin C is a better marker for GFR than that of creatinine.
The overall correlation between cystatin C and GFR was significantly stronger than that between creatinine and GFR. Moreover, the cystatin C concentration was significantly correlated to GFR for subjects with normal renal function as well as for patients with reduced GFR. This was not the case for creatinine. Earlier comparisons of the serum concentrations of cystatin C and creatinine as markers for GFR, in which enzyme-amplified single radial immunodiffusion was used to determine cystatin C, failed to clearly demonstrate the superiority of cystatin C as a marker for GFR (5, 6). However, the immunodiffusion-based method is much less precise than the PET assay described here and therefore does not fully exploit the advantages of cystatin C concentrations over creatinine concentrations for diagnostic purposes. Theoretically, cystatin C should have several advantages as a marker for the GFR. Because the production rate of creatinine is determined mainly by muscular mass, the rate is quite variable.
In addition, the elimination pathways for creatinine are complex and include, besides glomerular filtration, tubular secretion and elimination via the intestine. Cystatin C, in contrast, is a direct gene product, produced at a constant rate by virtually all body tissues, and is probably eliminated from blood almost exclusively by glomerular filtration (4) (5) (6) (7) (8) .
Consequently, it is not surprising that the diagnostic accuracy of serum cystatin C was superior to that of creatinine in discriminating between subjects with normal renal function and those with reduced GFR (Fig. 3) . For example, accurate detection of renal dysfunction in 90% of our subjects with reduced GFR (90% diagnostic sensitivity)
would require cutoff limits of 65 jmolfL for creatinine and 0.90 mg/L for cystatin C. Such limits for creatinine would result in falsely positive result in 67% of the subjects with normal renal function. The corresponding false-positive rate for cystatin C is 20%. Sensitivity and specificity were greater for serum cystatin C than for serum creatinine over the entire range of possible cutoff limits. Thus, both when the object is to exclude with certainty individuals with normal GFR (specificity) and when it is important to identify individuals with GFR impairment (sensitivity), serum cystatin C is a more efficient diagnostic tool than serum creatinine. A recent report on the serum concentration of cystatin C as determined by a sandwich enzyme immunoassay supports the notion that the cystatin C concentration has a greater diagnostic sensitivity for demonstrating reduced kidney function than does the concentration of creatinine (10).
In conclusion, serum cystatin C seems to be a promising marker for GFR, and the PET assay for cystatin C we describe appears suitable for both urgent and nonurgent routine quantification of cystatin C in serum. 
